Table 5. Multivariate associations between SNPs and PCa outcomes.
| SNP | Chr | Gene | Minor Allele | MAF | HR (95% CI) | P value |
|---|---|---|---|---|---|---|
|
Biochemical recurrence | ||||||
| rs13385191 | 2 | C2orf43 | A | 0.27 | 1.36 (1.03–1.81) | 0.02 |
| rs339331 | 6 | RFX6/GPRC6A | C | 0.15 | 1.47 (1.04–2.08) | 0.02 |
|
Castrate metastasis | ||||||
| rs13385191 | 2 | C2orf43 | A | 0.27 | 1.28 (1.03–1.60) | 0.02 |
| rs1894292 | 4 | AFM,RASSF6 | A | 0.42 | 1.25 (1.01–1.54) | 0.03 |
| rs17178655 | 10 | MSMB | A | 0.21 | 0.73 (0.55–0.97) | 0.03 |
| rs11067228 | 12 | OSTF1P1 | G | 0.48 | 0.79 (0.63–0.99) | 0.04 |
|
Prostate cancer-specific mortality | ||||||
| rs11902236 | 2 | TAF1B:GRHL1 | A | 0.34 | 0.78 (0.62–0.98) | 0.03 |
| rs4857841 | 3 | EEFSEC | A | 0.31 | 0.78 (0.62–0.98) | 0.04 |
Abbreviations: Chr=chromosome; CI=confidence interval; HR=hazard ratios; MAF=minor allele frequency; SNP=single-nucleotide polymorphism.
NOTE: Each SNP was individually assessed in separate multivariable models, controlling for age at prostate cancer diagnosis, PSA at diagnosis, clinical stage and biopsy Gleason grade.